Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Bortezomib Treatment for Patients With Anti-N-Methyl-d-Aspartate Receptor Encephalitis.

Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I.

JAMA Neurol. 2016 Aug 15. doi: 10.1001/jamaneurol.2016.2588. [Epub ahead of print] No abstract available.

PMID:
27533122
2.

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A.

Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.

PMID:
27358379
3.

[ASCO-update 2015 - highlights of the 51. meeting of the american society of clinical oncology/ASCO 2015].

Lorenzen S, Arnold D, Fottner C, Leichsenring J, Moehler M, Seufferlein T, Vogel A, Weber MM, Reinacher-Schick A.

Z Gastroenterol. 2016 Feb;54(2):167-72. doi: 10.1055/s-0041-111632. Epub 2016 Feb 8. German.

PMID:
26854837
4.

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D.

Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

PMID:
26361971
5.

[Clinically relevant, gender-specific differences in colorectal carcinoma (CRC)].

Höffken N, Leichsenring J, Reinacher-Schick A.

Z Gastroenterol. 2015 Aug;53(8):782-8. doi: 10.1055/s-0035-1553476. Epub 2015 Aug 18. Review. German.

PMID:
26284326
6.

Multiple cerebral infarctions in a young patient with heroin-induced hypereosinophilic syndrome.

Bolz J, Meves SH, Kara K, Reinacher-Schick A, Gold R, Krogias C.

J Neurol Sci. 2015 Sep 15;356(1-2):193-5. doi: 10.1016/j.jns.2015.06.031. Epub 2015 Jun 16.

PMID:
26104570
7.

Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.

Nöpel-Dünnebacke S, Schulmann K, Reinacher-Schick A, Porschen R, Schmiegel W, Tannapfel A, Graeven U.

Z Gastroenterol. 2014 Dec;52(12):1394-401. doi: 10.1055/s-0034-1366781. Epub 2014 Dec 4.

PMID:
25474278
8.

[Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].

Schneider R, Schneider C, Büttner R, Reinacher-Schick A, Tannapfel A, Fürst A, Rüschoff J, Jakobeit C, Royer-Pokora B, Möslein G.

Zentralbl Chir. 2015 Dec;140(6):591-9. doi: 10.1055/s-0034-1368480. Epub 2014 Nov 5. German.

PMID:
25372301
9.

Colorectal Cancer: Personalized Therapy.

Leichsenring J, Koppelle A, Reinacher-Schick A.

Gastrointest Tumors. 2014 May;1(4):209-20. doi: 10.1159/000380790. Epub 2015 Apr 15. Review.

10.

Colorectal Adenoma - Resection Techniques and Surveillance.

Kähler G, Reinacher-Schick A.

Viszeralmedizin. 2014 Feb;30(1):8-9. doi: 10.1159/000360561. No abstract available.

11.

Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.

El-Mashtoly SF, Petersen D, Yosef HK, Mosig A, Reinacher-Schick A, Kötting C, Gerwert K.

Analyst. 2014 Mar 7;139(5):1155-61. doi: 10.1039/c3an01993d. Epub 2014 Jan 15.

PMID:
24427772
12.

[S3-guideline exocrine pancreatic cancer].

Seufferlein T, Porzner M, Becker T, Budach V, Ceyhan G, Esposito I, Fietkau R, Follmann M, Friess H, Galle P, Geissler M, Glanemann M, Gress T, Heinemann V, Hohenberger W, Hopt U, Izbicki J, Klar E, Kleeff J, Kopp I, Kullmann F, Langer T, Langrehr J, Lerch M, Löhr M, Lüttges J, Lutz M, Mayerle J, Michl P, Möller P, Molls M, Münter M, Nothacker M, Oettle H, Post S, Reinacher-Schick A, Röcken C, Roeb E, Saeger H, Schmid R, Schmiegel W, Schoenberg M, Siveke J, Stuschke M, Tannapfel A, Uhl W, Unverzagt S, van Oorschot B, Vashist Y, Werner J, Yekebas E; Guidelines Programme Oncology AWMF; German Cancer Society eV; German Cancer Aid.

Z Gastroenterol. 2013 Dec;51(12):1395-440. doi: 10.1055/s-0033-1356220. Epub 2013 Dec 11. German. No abstract available.

13.

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.

Giessen C, Graeven U, Laubender RP, Modest DP, Schulz C, Porschen R, Schmiegel W, Reinacher-Schick A, Hegewisch-Becker S, Stintzing S, Heinemann V.

Ann Oncol. 2013 Dec;24(12):3051-5. doi: 10.1093/annonc/mdt402. Epub 2013 Oct 14.

14.

Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.

Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ.

Acta Oncol. 2014 Mar;53(3):392-8. doi: 10.3109/0284186X.2013.833346. Epub 2013 Sep 12.

PMID:
24024696
15.

[S3-guideline colorectal cancer version 1.0].

Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W; Leitlinienprogramm Onkologie der AWMF; Deutschen Krebsgesellschaft e. V; Deutschen Krebshilfe e. V.

Z Gastroenterol. 2013 Aug;51(8):753-854. doi: 10.1055/s-0033-1350264. Epub 2013 Aug 16. German. No abstract available.

16.

ß-Catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy.

Brand L, Munding J, Pox CP, Ziebarth W, Reiser M, Hüppe D, Schmiegel W, Reinacher-Schick A, Tannapfel A.

Int J Colorectal Dis. 2013 Aug;28(8):1091-8. doi: 10.1007/s00384-013-1667-z. Epub 2013 Mar 21.

PMID:
23516071
17.

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.

Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U.

Ann Oncol. 2013 Jun;24(6):1580-7. doi: 10.1093/annonc/mdt028. Epub 2013 Mar 4.

18.

[Colorectal carcinoma: what's new?].

Pox C, Schmiegel W, Reinacher-Schick A.

Dtsch Med Wochenschr. 2012 Dec;137(49):2577-80. doi: 10.1055/s-0032-1327268. Epub 2012 Nov 27. Review. German. No abstract available.

PMID:
23188639
19.

Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma.

Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnouj A, Wos A, Mayerle J, Munding J, Kost D, Reinacher-Schick A, Liffers S, Schroers R, Chromik AM, Meyer HE, Uhl W, Klein-Scory S, Weiss FU, Stephan C, Schwarte-Waldhoff I, Lerch MM, Tannapfel A, Schmiegel W, Andersen CL, Hahn SA.

Int J Cancer. 2013 Jan 15;132(2):E48-57. doi: 10.1002/ijc.27791. Epub 2012 Sep 14.

20.

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.

Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A.

BMC Cancer. 2012 Aug 9;12:349. doi: 10.1186/1471-2407-12-349.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk